Overview

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Status:
Completed

Trial end date:
2013-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major depression associated with bipolar I disorder.

Phase:

Phase 3

Details

Lead Sponsor:

Cephalon

Treatments:

Armodafinil
Modafinil